Delivery Order SPE2DB20D7066-SPE2DB26FC1MY
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,944.73 to AmerisourceBergen Drug Corp for the supply of Nitrofurantoin 25 mg/5 ml suspension in 230 ml quantities. This contract was competitively awarded with no set-aside designation and carries a firm fixed price structure. The work is scheduled for completion by November 3, 2025, with the place of performance located in Conshohocken, Pennsylvania, the company's corporate headquarters. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Nitrofurantoin 25 mg/5 ml suspension in a 230 ml quantity, with a ceiling value of $6,907.65. This contract represents a firm fixed price delivery order with an ultimate completion date of July 30, 2025, and carries no set-aside designation, indicating it was competitively awarded. The pharmaceutical product will be delivered to the place of performance in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 23, 2025, for the supply of Nitrofurantoin 25 mg/5 mL suspension (230 mL quantity) with a ceiling value of $5,067.68. This is a firm fixed-price delivery order with an ultimate completion date of June 24, 2025, and no set-aside designation was utilized. The award was competitively awarded to AmerisourceBergen's Corporate Office, with performance to be conducted at the company's location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Nitrofurantoin 25 mg/5 ml suspension in a 230 ml quantity, valued at $3,014.36. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 21, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was competed among qualified vendors in the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Nitrofurantoin 25 mg/5 ml suspension in a 230 ml quantity, valued at $9,138.12 under firm fixed price terms. This non-set-aside, competitively awarded contract is classified as a delivery order with an ultimate completion date of August 28, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a single transaction...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,649.72 to AmerisourceBergen Drug Corp for the supply of Nitrofurantoin 25 mg/5 mL suspension in a 230 mL quantity. This contract was competitively awarded without a set-aside designation and operates under firm fixed price terms, with an ultimate completion date of August 21, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,128.21 to AmerisourceBergen Drug Corp for Nitrofurantoin 25 mg/5 mL Suspension (230 mL) on August 19, 2025, with an ultimate completion date of August 20, 2025. This contract was awarded competitively with no set-aside designation under firm fixed price terms. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. Nitrofurantoin is a...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,927,031 units of Nitrofurantoin 25 mg/5 ml suspension in 240 ml bottles. The $74,193.86 contract has a performance period through March 12, 2024 and does not have a set-aside designation. Amerisourcebergen Drug Corp also holds an indefinite delivery contract with DLA valued at up to $999,999,999.00 through...
- This federal contract award was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Nitrofurantoin 25 mg/5 ml suspension in 240 ml bottles. The $15,154.76 firm-fixed-price delivery order contract has a performance period through September 18, 2024 and is not set aside for any specific business type. Amerisourcebergen holds an Indefinite Delivery Contract (IDC) with the DLA...
- This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $15,539.37 firm fixed price delivery order is for the supply of 240 mL bottles of Nitrofurantoin 25 mg/5 mL suspension medication. The contract has an ultimate completion date of January 6, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract with the DLA Troop Support Medical through November 2026, which serves as a primary...
- SPE2DB20D7066Indefinite Delivery Contract
- SPE2DB20D7066-SPE2DB26FC1MYDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Nitrofurantoin 25 mg/5 ml suspension (230 ml quantity) with a contract ceiling value of $4,737.27. This is a firm fixed price delivery order with an ultimate completion date of November 3, 2025, and represents a competitively awarded, non-set-aside contract. The work will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare systems. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor providing a broad range of medications, vaccines, and medical supplies to support Defense Health Agency and other government healthcare customers worldwide. The contract demonstrates the company's established capability to fulfill federal medical procurement requirements across multiple therapeutic domains on a competitive basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 10/31/25 |